BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease

Summary

A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of BPDO-1603 in patients with moderate-to-severe Alzheimer's disease

Timeline

Start

2020-02-27

Primary completion

2022-02-28

Completion

2023-03-01

Drugs

Indications